Skip to main content
SpringerLink
Log in

Gastrinoma

  • Chapter
Book cover Neuroendocrine Tumours

  • 1638 Accesses

Abstract

Gastrinomas are rare tumors of the neuroendocrine system, occurring within the pancreas and duodenum. The annual incidence is estimated at 0.5 per million of the population [1]. Overproduction of gastrin by these tumors produces a sustained increase in gastric acid secretion, leading to clinical manifestations of complicated peptic ulcer disease known as the Zollinger-Ellison syndrome (ZES) [2]. Although most gastrinomas grow slowly, over 60 % are malignant and 25 % show rapid aggressive behavior [3–5]. Most commonly gastrinomas metastasize to regional lymph nodes and the liver, and it is this malignant potential which has become increasingly important since the introduction of effective medical therapy to control gastric acid secretion. Gastrinomas can occur sporadically or in a familial pattern as a component of the multiple endocrine neoplasia type 1 (MEN1) syndrome [3, 6, 7]. Given that the endocrinopathy associated with these tumors can be well controlled medically, the role of surgical resection in the setting of advanced disease and in patients with MEN1 syndrome is the subject of continued debate.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ellison EC, Johnson JA (2009) The Zollinger-Ellison syndrome: a comprehensive review of historical, scientific, and clinical considerations. Curr Probl Surg 46:13–106

    PubMed  Google Scholar 

  2. Zollinger RM, Ellison EH (1955) Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 142:709–723; discussion, 724–728

    PubMed Central  CAS  PubMed  Google Scholar 

  3. Ellison EH, Wilson SD (1964) The Zollinger-Ellison syndrome: re-appraisal and evaluation of 260 registered cases. Ann Surg 160:512–530

    PubMed Central  CAS  PubMed  Google Scholar 

  4. Ellison EC, Sparks J, Verducci JS et al (2006) 50-year appraisal of gastrinoma: recommendations for staging and treatment. J Am Coll Surg 202:897–905

    PubMed  Google Scholar 

  5. Osefo N, Ito T, Jensen RT (2009) Gastric acid hypersecretory states: recent insights and advances. Curr Gastroenterol Rep 11:433–441

    PubMed Central  PubMed  Google Scholar 

  6. Bartsch D, Kopp I, Bergenfelz A et al (1998) MEN1 gene mutations in 12 MEN1 families and their associated tumors. Eur J Endocrinol 139:416–420

    CAS  PubMed  Google Scholar 

  7. Jensen RT, Berna MJ, Bingham DB, Norton JA (2008) Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 113:1807–1843

    PubMed Central  PubMed  Google Scholar 

  8. Sailer S, Zinninger MM (1946) Massive islet cell tumor of the pancreas without hypoglycemia. Surg Gynecol Obstet 82:301

    CAS  PubMed  Google Scholar 

  9. Yeung MJ, Pasieka JL (2009) Gastrinomas: a historical perspective. J Surg Oncol 100:425–433

    PubMed  Google Scholar 

  10. Gregory RA, Tracy HJ, French JM, Sircus W (1960) Extraction of a gastrin-like substance from a pancreatic tumour in a case of Zollinger-Ellison syndrome. Lancet 1:1045–1048

    CAS  PubMed  Google Scholar 

  11. Gregory RA, Grossman MI, Tracy HJ, Bentley PH (1967) Nature of the gastric secretagogue in Zollinger-Ellison tumours. Lancet 2:543–544

    CAS  PubMed  Google Scholar 

  12. McGuigan JE, Trudeau WL (1968) Immunochemical measurement of elevated levels of gastrin in the serum of patients with pancreatic tumors of the Zollinger-Ellison variety. N Engl J Med 278:1308–1313

    CAS  PubMed  Google Scholar 

  13. Murugesan SV, Varro A, Pritchard DM (2009) Review article: strategies to determine whether hypergastrinaemia is due to Zollinger-Ellison syndrome rather than a more common benign cause. Aliment Pharmacol Ther 29:1055–1068

    CAS  PubMed  Google Scholar 

  14. Isenberg JI, Walsh JH, Passaro EJ, Moore EW, Grossman MI (1972) Unusual effect of secretin on serum gastrin, serum calcium, and gastric acid secretion in a patient with suspected Zollinger-Ellison syndrome. Gastroenterology 62:626–631

    CAS  PubMed  Google Scholar 

  15. Rawson AB, England MT, Gillam GG, French JM, Stammers FA (1960) Zollinger-Ellison syndrome with diarrhoea and malabsorption. Observations on a patient before and after pancreatic islet-cell tumour removal with-out resort. Lancet 2:131–134

    Google Scholar 

  16. Oberhelman HAJ, Nelsen TS (1964) Surgical consideration in the management of ulcerogenic tumors of the pancreas and duodenum. Am J Surg 108:132–141

    PubMed  Google Scholar 

  17. Norton JA, Alexander HR, Fraker DL, Venzon DJ, Gibril F, Jensen RT (2004) Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome? Ann Surg 239:617–625; discussion 626

    PubMed Central  PubMed  Google Scholar 

  18. Oberhelman HAJ, Nelsen TS, Johnson ANJ, Dragstedt LR (1961) Ulcerogenic tumors of the duodenum. Ann Surg 153:214–227

    Google Scholar 

  19. Thompson NW, Vinik AI, Eckhauser FE (1989) Microgastrinomas of the duodenum. A cause of failed operations for the Zollinger-Ellison syndrome. Ann Surg 209:396–404

    PubMed Central  CAS  PubMed  Google Scholar 

  20. Thompson NW, Pasieka J, Fukuuchi A (1993) Duodenal gastrinomas, duodenotomy, and duodenal exploration in the surgical management of Zollinger-Ellison syndrome. World J Surg 17:455–462

    CAS  PubMed  Google Scholar 

  21. Underdahl LO, Woolner LB, Black BM (1953) Multiple endocrine adenomas; report of 8 cases in which the parathyroids, pituitary and pancreatic islets were involved. J Clin Endocrinol Metab 13:20–47

    Google Scholar 

  22. Wermer P (1954) Genetic aspects of adenomatosis of endocrine glands. Am J Med 16:363–371

    CAS  PubMed  Google Scholar 

  23. Metz DC (2012) Diagnosis of the Zollinger-Ellison syndrome. Clin Gastroenterol Hepatol 10:126–130

    PubMed  Google Scholar 

  24. Roy PK, Venzon DJ, Shojamanesh H et al (2000) Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore) 79:379–411

    CAS  Google Scholar 

  25. Corleto VD, Annibale B, Gibril F et al (2001) Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome? Aliment Pharmacol Ther 15:1555–1561

    CAS  PubMed  Google Scholar 

  26. Yao JC, Eisner MP, Leary C et al (2007) Population-based study of islet cell carcinoma. Ann Surg Oncol 14:3492–3500

    PubMed Central  PubMed  Google Scholar 

  27. Soga J, Yakuwa Y (1998) The gastrinoma/Zollinger-Ellison syndrome: statistical evaluation of a Japanese series of 359 cases. J Hepatobiliary Pancreat Surg 5:77–85

    CAS  PubMed  Google Scholar 

  28. Roy PK, Venzon DJ, Feigenbaum KM et al (2001) Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosi-- prospective NIH study of 235 patients and a review of 984 cases in the literature. Medicine (Baltimore) 80:189–222

    Google Scholar 

  29. Fendrich V, Langer P, Waldmann J, Bartsch DK, Rothmund M (2007) Management of sporadic and multiple endocrine neoplasia type 1 gastrinomas. Br J Surg 94:1331–1341

    CAS  PubMed  Google Scholar 

  30. Ellison EC, Sparks J (2003) Zollinger-Ellison syndrome in the era of effective acid suppression: are we unknowingly growing tumors? Am J Surg 186:245–248

    PubMed  Google Scholar 

  31. Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT (2006) Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore) 85:295–330

    CAS  Google Scholar 

  32. Berna MJ, Hoffmann KM, Long SH, Serrano J, Gibril F, Jensen RT (2006) Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore) 85:331–364

    CAS  Google Scholar 

  33. Metz DC, Buchanan M, Purich E, Fein S (2001) A randomized controlled crossover study comparing synthetic porcine and human secretins with biologically derived porcine secretin to diagnose Zollinger-Ellison syndrome. Aliment Pharmacol Ther 15:669–676

    CAS  PubMed  Google Scholar 

  34. Vezzosi D, Walter T, Laplanche A et al (2011) Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study. Int J Biol Markers 26:94–101

    CAS  PubMed  Google Scholar 

  35. Abou-Saif A, Gibril F, Ojeaburu JV et al (2003) Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas. Cancer 98:249–261

    CAS  PubMed  Google Scholar 

  36. Norton JA, Fraker DL, Alexander HR et al (2006) Surgery increases survival in patients with gastrinoma. Ann Surg 244:410–419

    PubMed Central  PubMed  Google Scholar 

  37. Stabile BE, Morrow DJ, Passaro EJ (1984) The gastrinoma triangle: operative implications. Am J Surg 147:25–31

    CAS  PubMed  Google Scholar 

  38. Zogakis TG, Gibril F, Libutti SK et al (2003) Management and outcome of patients with sporadic gastrinoma arising in the duodenum. Ann Surg 238:42–48

    PubMed Central  PubMed  Google Scholar 

  39. Sugg SL, Norton JA, Fraker DL et al (1993) A prospective study of intraoperative methods to diagnose and resect duodenal gastrinomas. Ann Surg 218:138–144

    PubMed Central  CAS  PubMed  Google Scholar 

  40. Norton JA, Fraker DL, Alexander HR, Jensen RT (2012) Value of surgery in patients with negative imaging and sporadic Zollinger-Ellison syndrome. Ann Surg 256:509–517

    PubMed Central  PubMed  Google Scholar 

  41. Pipeleers-Marichal M, Donow C, Heitz PU, Kloppel G (1993) Pathologic aspects of gastrinomas in patients with Zollinger-Ellison syndrome with and without multiple endocrine neoplasia type I. World J Surg 17:481–488

    CAS  PubMed  Google Scholar 

  42. Phan GQ, Yeo CJ, Hruban RH, Littemoe KD, Pitt HA, Cameron JL (1998) Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg 2:473–482

    CAS  PubMed  Google Scholar 

  43. Jensen RT, Cadiot G, Brandi ML et al (2012) ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 95:98–119

    PubMed Central  CAS  PubMed  Google Scholar 

  44. Bartsch DK, Fendrich V, Langer P, Celik I, Kann PH, Rothmund M (2005) Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 242:757–764; discussion 764–766

    PubMed Central  PubMed  Google Scholar 

  45. Bartsch DK, Langer P, Rothmund M (2007) Surgical aspects of gastrinoma in multiple endocrine neoplasia type 1. Wien Klin Wochenschr 119:602–608

    PubMed  Google Scholar 

  46. Wu PC, Alexander HR, Bartlett DL et al (1997) A prospective analysis of the frequency, location, and curability of ectopic (nonpancreaticoduodenal, nonnodal) gastrinoma. Surgery 122:1176–1182

    CAS  PubMed  Google Scholar 

  47. Harvey A, Pasieka JL, Al-Bischer H, Dixon E (2012) Primary hepatic gastrinomas causing Zollinger-Ellison syndrome: rare and challenging diagnosis. Cancers 4:130–140

    PubMed Central  PubMed  Google Scholar 

  48. Hirasawa K, Yamada M, Kitagawa M et al (2000) Ovarian mucinous cystadenocarcinoma as a cause of Zollinger-Ellison syndrome: report of a case and review of the literature. Am J Gastroenterol 95:1348–1351

    CAS  PubMed  Google Scholar 

  49. Norton JA, Alexander HR, Fraker DL, Venzon DJ, Gibril F, Jensen RT (2003) Possible primary lymph node gastrinoma: occurrence, natural history, and predictive factors: a prospective study. Ann Surg 237:650–657; discussion 657–659

    PubMed Central  PubMed  Google Scholar 

  50. Anlauf M, Enosawa T, Henopp T et al (2008) Primary lymph node gastrinoma or occult duodenal microgastrinoma with lymph node metastases in a MEN1 patient: the need for a systematic search for the primary tumor. Am J Surg Pathol 32:1101–1105

    PubMed  Google Scholar 

  51. Norton JA, Fraker DL, Alexander HR et al (1999) Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 341:635–644

    CAS  PubMed  Google Scholar 

  52. Giovinazzo F, Butturini G, Monsellato D, Malleo G, Marchegiani G, Bassi C (2013) Lymph nodes metastasis and recurrences justify an aggressive treatment of gastrinoma. Updates Surg 65:19–24

    PubMed  Google Scholar 

  53. Weber HC, Venzon DJ, Lin JT et al (1995) Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 108:1637–1649

    CAS  PubMed  Google Scholar 

  54. Yu F, Venzon DJ, Serrano J et al (1999) Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 17:615–630

    CAS  PubMed  Google Scholar 

  55. Metz DC, Jensen RT (2008) Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 135:1469–1492

    PubMed Central  CAS  PubMed  Google Scholar 

  56. Gibril F, Doppman JL, Reynolds JC et al (1998) Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management. J Clin Oncol 16:1040–1053

    CAS  PubMed  Google Scholar 

  57. Goebel SU, Heppner C, Burns AL et al (2000) Genotype/phenotype correlation of multiple endocrine neoplasia type 1 gene mutations in sporadic gastrinomas. J Clin Endocrinol Metab 85:116–123

    CAS  PubMed  Google Scholar 

  58. Kawamura J, Shimada Y, Komoto I et al (2005) Multiple endocrine neoplasia type 1 gene mutations in sporadic gastrinomas in Japan. Oncol Rep 14:47–52

    CAS  PubMed  Google Scholar 

  59. Wild A, Langer P, Celik I, Chaloupka B, Bartsch DK (2002) Chromosome 22q in pancreatic endocrine tumors: identification of a homozygous deletion and potential prognostic associations of allelic deletions. Eur J Endocrinol 147:507–513

    CAS  PubMed  Google Scholar 

  60. Chen YJ, Vortmeyer A, Zhuang Z, Gibril F, Jensen RT (2004) X-chromosome loss of heterozygosity frequently occurs in gastrinomas and is correlated with aggressive tumor growth. Cancer 100:1379–1387

    PubMed  Google Scholar 

  61. Serrano J, Goebel SU, Peghini PL, Lubensky IA, Gibril F, Jensen RT (2000) Alterations in the p16INK4a/CDKN2A tumor suppressor gene in gastrinomas. J Clin Endocrinol Metab 85:4146–4156

    CAS  PubMed  Google Scholar 

  62. Capelli P, Martignoni G, Pedica F et al (2009) Endocrine neoplasms of the pancreas: pathologic and genetic features. Arch Pathol Lab Med 133:350–364

    PubMed  Google Scholar 

  63. Alexander HR, Fraker DL, Norton JA et al (1998) Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 228:228–238

    PubMed Central  CAS  PubMed  Google Scholar 

  64. Gibril F, Reynolds JC, Doppman JL et al (1996) Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 125:26–34

    CAS  PubMed  Google Scholar 

  65. Trudeau WL, McGuigan JE (1969) Effects of calcium on serum gastrin levels in the zollinger-Ellison syndrome. N Engl J Med 281:862–866

    CAS  PubMed  Google Scholar 

  66. Termanini B, Gibril F, Reynolds JC et al (1997) Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 112:335–347

    CAS  PubMed  Google Scholar 

  67. Fusaroli P, Kypraios D, Caletti G, Eloubeidi MA (2012) Pancreatico-biliary endoscopic ultrasound: a systematic review of the levels of evidence, performance and outcomes. World J Gastroenterol 18:4243–4256

    PubMed Central  PubMed  Google Scholar 

  68. Imamura M, Takahashi K (1993) Use of selective arterial secretin injection test to guide surgery in patients with Zollinger-Ellison syndrome. World J Surg 17:433–438

    CAS  PubMed  Google Scholar 

  69. Wada M, Komoto I, Doi R, Imamura M (2002) Intravenous calcium injection test is a novel complementary procedure in differential diagnosis for gastrinoma. World J Surg 26:1291–1296

    PubMed  Google Scholar 

  70. Sundin A, Garske U, Orlefors H (2007) Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 21:69–85

    CAS  PubMed  Google Scholar 

  71. Gabriel M, Decristoforo C, Kendler D et al (2007) 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48:508–518

    CAS  PubMed  Google Scholar 

  72. Frilling A, Sotiropoulos GC, Radtke A et al (2010) The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg 252:850–856

    PubMed  Google Scholar 

  73. Kulke MH, Anthony LB, Bushnell DL et al (2010) NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 39:735–752

    PubMed Central  PubMed  Google Scholar 

  74. Sarmiento JM, Farnell MB, Que FG, Nagorney DM (2002) Pancreaticoduodenectomy for islet cell tumors of the head of the pancreas: long-term survival analysis. World J Surg 26:1267–1271

    PubMed  Google Scholar 

  75. Bartsch DK, Waldmann J, Fendrich V et al (2012) Impact of lymphadenectomy on survival after surgery for sporadic gastrinoma. Br J Surg 99:1234–1240

    CAS  PubMed  Google Scholar 

  76. Maire F, Sauvanet A, Couvelard A et al (2012) Recurrence after surgical resection of gastrinoma: who, when, where and why? Eur J Gastroenterol Hepatol 24:368–374

    PubMed  Google Scholar 

  77. Grobmyer SR, Hochwald SN (2010) Reoperative surgery for the Zollinger-Ellison syndrome. Adv Surg 44:327–346

    PubMed  Google Scholar 

  78. Lewis MA, Hubbard J (2011) Multimodal liver-directed management of neuroendocrine hepatic metastases. Int J Hepatol 2011:452343

    PubMed Central  PubMed  Google Scholar 

  79. Karabulut K, Akyildiz HY, Lance C et al (2011) Multimodality treatment of neuroendocrine liver metastases. Surgery 150:316–325

    PubMed  Google Scholar 

  80. Mayo SC, de Jong MC, Pulitano C et al (2010) Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 17:3129–3136

    PubMed  Google Scholar 

  81. Norton JA, Doherty GM, Fraker DL et al (1998) Surgical treatment of localized gastrinoma within the liver: a prospective study. Surgery 124:1145–1152

    CAS  PubMed  Google Scholar 

  82. Mayo SC, de Jong MC, Pawlik TM (2011) Surgical management and emerging therapies to prolong survival in metastatic neuroendocrine cancer. Ann Surg Oncol 18(Suppl 3):S220–S221; author reply S222–3

    PubMed  Google Scholar 

  83. Touzios JG, Kiely JM, Pitt SC et al (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241:776–783; discussion 783–785

    PubMed Central  PubMed  Google Scholar 

  84. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197:29–37

    PubMed  Google Scholar 

  85. Gurusamy KS, Ramamoorthy R, Sharma D, Davidson BR (2009) Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev (2):CD007060

    Google Scholar 

  86. Zappa M, Abdel-Rehim M, Hentic O, Vullierme MP, Ruszniewski P, Vilgrain V (2012) Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract. Target Oncol 7:107–116

    PubMed  Google Scholar 

  87. John BJ, Davidson BR (2012) Treatment options for unresectable neuroendocrine liver metastases. Expert Rev Gastroenterol Hepatol 6:357–369

    CAS  PubMed  Google Scholar 

  88. Gupta S, Yao JC, Ahrar K et al (2003) Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 9:261–267

    PubMed  Google Scholar 

  89. Kennedy AS, Dezarn WA, McNeillie P et al (2008) Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 31:271–279

    PubMed  Google Scholar 

  90. King J, Quinn R, Glenn DM et al (2008) Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113:921–929

    PubMed  Google Scholar 

  91. Lau WY, Kennedy AS, Kim YH et al (2012) Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys 82:401–407

    PubMed  Google Scholar 

  92. De Jong M, Valkema R, Jamar F et al (2002) Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 32:133–140

    PubMed  Google Scholar 

  93. Frilling A, Akerstrom G, Falconi M et al (2012) Neuroendocrine tumor disease: an evolving landscape. Endocr Relat Cancer 19:R163–R185

    CAS  PubMed  Google Scholar 

  94. Frilling A, Weber F, Saner F et al (2006) Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery 140:968–976; discussion 976–977

    PubMed  Google Scholar 

  95. Grama D, Eriksson B, Martensson H et al (1992) Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes. World J Surg 16:632–639

    CAS  PubMed  Google Scholar 

  96. Kouvaraki MA, Ajani JA, Hoff P et al (2004) Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22:4762–4771

    CAS  PubMed  Google Scholar 

  97. Shojamanesh H, Gibril F, Louie A et al (2002) Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 94:331–343

    CAS  PubMed  Google Scholar 

  98. Raymond E, Dahan L, Raoul JL et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513

    CAS  PubMed  Google Scholar 

  99. Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514–523

    PubMed Central  CAS  PubMed  Google Scholar 

  100. Yao JC, Lagunes DR, Kulke MH (2013) Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned. Oncologist 18:525–532

    PubMed Central  CAS  PubMed  Google Scholar 

  101. Yao JC, Phan AT, Jehl V, Shah G, Meric-Bernstam F (2013) Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience. Cancer Res 73:1449–1453

    CAS  PubMed  Google Scholar 

  102. Hammel P, Hentic O, Neuzillet C, Faivre S, Raymond E, Ruszniewski P (2012) New treatment options with cytotoxic agents in neuroendocrine tumours. Target Oncol 7:169–172

    PubMed  Google Scholar 

  103. Raymond E, Dreyer C, Faivre S (2012) Targeting neuroendocrine tumor: mixing standard options with novel therapies. Target Oncol 7:151–152

    PubMed  Google Scholar 

  104. Doherty GM, Thompson NW (2003) Multiple endocrine neoplasia type 1: duodenopancreatic tumours. J Intern Med 253:590–598

    CAS  PubMed  Google Scholar 

  105. Akerstrom G, Stalberg P, Hellman P (2012) Surgical management of pancreatico-duodenal tumors in multiple endocrine neoplasia syndrome type 1. Clinics (Sao Paulo) 67(Suppl 1):173–178

    Google Scholar 

  106. Schimmack S, Svejda B, Lawrence B, Kidd M, Modlin IM (2011) The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbecks Arch Surg 396:273–298

    PubMed  Google Scholar 

  107. Gibril F, Jensen RT (2005) Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome. Curr Gastroenterol Rep 7:114–121

    PubMed  Google Scholar 

  108. Ito T, Igarashi H, Uehara H, Berna MJ, Jensen RT (2013) Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore) 92:135–181

    CAS  Google Scholar 

  109. Wilson SD, Krzywda EA, Zhu YR et al (2008) The influence of surgery in MEN-1 syndrome: observations over 150 years. Surgery 144:695–701; discussion 701–702

    PubMed  Google Scholar 

  110. Kloppel G, Anlauf M, Perren A (2007) Endocrine precursor lesions of gastroenteropancreatic neuroendocrine tumors. Endocr Pathol 18:150–155

    PubMed  Google Scholar 

  111. Thompson NW, Bondeson AG, Bondeson L, Vinik A (1989) The surgical treatment of gastrinoma in MEN I syndrome patients. Surgery 106:1081–1085; discussion 1085–1086

    CAS  PubMed  Google Scholar 

  112. Hausman MSJ, Thompson NW, Gauger PG, Doherty GM (2004) The surgical management of MEN-1 pancreatoduodenal neuroendocrine disease. Surgery 136:1205–1211

    PubMed  Google Scholar 

  113. Gauger PG, Doherty GM, Broome JT, Miller BS, Thompson NW (2009) Completion pancreatectomy and duodenectomy for recurrent MEN-1 pancreaticoduodenal endocrine neoplasms. Surgery 146:801–806; discussion 807–808

    PubMed  Google Scholar 

  114. Triponez F, Goudet P, Dosseh D et al (2006) Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg 30:654–662; discussion 663–664

    PubMed  Google Scholar 

  115. Thompson NW (1998) Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med 243:495–500

    CAS  PubMed  Google Scholar 

  116. Norton JA, Alexander HR, Fraker DL, Venzon DJ, Gibril F, Jensen RT (2001) Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg 234:495–505; discussion 505–506

    PubMed Central  CAS  PubMed  Google Scholar 

  117. Kouvaraki MA, Shapiro SE, Cote GJ et al (2006) Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg 30:643–653

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cumming’s School of Medicine, Department of Surgery, Section of Genernal Surgery and Surgical Onocoloy, University of Calgary and Foothills Medical Centre and Tom Baker Cancer Centre, 10th Floor North Tower, 1403 – 29 Street NW, Calgary, Alberta, T2N 2 T9, Canada

    Janice L. Pasieka MD, FRCSC, FACS & Anthony J. Chambers BSc, MBBS, MS, FRACS

Authors
  1. Janice L. Pasieka MD, FRCSC, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anthony J. Chambers BSc, MBBS, MS, FRACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Janice L. Pasieka MD, FRCSC, FACS .

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey

    Suayib Yalcin

  2. Department of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden

    Kjell Öberg

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Pasieka, J.L., Chambers, A.J. (2015). Gastrinoma. In: Yalcin, S., Öberg, K. (eds) Neuroendocrine Tumours. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45215-8_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-45215-8_13

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-45214-1

  • Online ISBN: 978-3-662-45215-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation